Eko Health's AI technology has shown groundbreaking potential in a new study conducted by Imperial College London, demonstrating its ability to predict major adverse cardiac events (MACE) and mortality with unmatched accuracy. By using Eko's Low Ejection Fraction AI, researchers identified patients with a significantly higher risk of heart attacks, heart failure, and hospitalization.
